See more : AGCO Corporation (AGCO) Income Statement Analysis – Financial Results
Complete financial analysis of UroGen Pharma Ltd. (URGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of UroGen Pharma Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- United Polyfab Gujarat Limited (UNITEDPOLY.NS) Income Statement Analysis – Financial Results
- Soditech SA (SEC.PA) Income Statement Analysis – Financial Results
- Bestway Global Holding Inc. (3358.HK) Income Statement Analysis – Financial Results
- MOGAN ENERJI (MOGAN.IS) Income Statement Analysis – Financial Results
- Qatar International Islamic Bank (Q.P.S.C) (QIIK.QA) Income Statement Analysis – Financial Results
UroGen Pharma Ltd. (URGN)
About UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 82.71M | 64.36M | 48.04M | 11.80M | 18.00K | 1.13M | 8.16M | 17.53M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 9.36M | 7.65M | 5.16M | 1.01M | 0.00 | 1.80M | 600.00K | 28.00K | 113.00K | 0.00 | 0.00 |
| Gross Profit | 73.35M | 56.70M | 42.89M | 10.79M | 18.00K | -675.00K | 7.56M | 17.50M | -113.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 88.68% | 88.11% | 89.27% | 91.45% | 100.00% | -59.84% | 92.65% | 99.84% | 0.00% | 0.00% | 0.00% |
| Research & Development | 45.61M | 52.91M | 47.64M | 47.31M | 49.30M | 36.93M | 18.70M | 10.29M | 10.52M | 4.01M | 2.33M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 60.20M | 39.57M | 8.81M | 6.42M | 1.90M | 890.00K | 1.06M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 93.27M | 82.84M | 87.54M | 90.22M | 60.20M | 39.57M | 8.81M | 6.42M | 1.90M | 890.00K | 1.06M |
| Other Expenses | 0.00 | 72.00K | 0.00 | 0.00 | -284.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 138.89M | 135.74M | 135.18M | 137.53M | 109.50M | 76.51M | 27.51M | 16.70M | 12.41M | 4.36M | 3.39M |
| Cost & Expenses | 148.25M | 143.40M | 140.33M | 138.54M | 109.50M | 78.31M | 28.11M | 16.73M | 12.41M | 4.36M | 3.39M |
| Interest Income | 2.64M | 1.01M | 212.00K | 1.63M | 4.62M | 1.87M | 0.00 | 1.00K | 0.00 | 120.00K | 83.00K |
| Interest Expense | 14.72M | 8.44M | 17.44M | 357.00K | 284.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.71M | 1.82M | 1.77M | 2.04M | 1.32M | 417.00K | 207.00K | 213.00K | 113.00K | 30.00K | 18.00K |
| EBITDA | -63.83M | -78.03M | -90.15M | -122.71M | -108.15M | -77.18M | -19.74M | 1.01M | -12.30M | -4.34M | -3.37M |
| EBITDA Ratio | -77.17% | -121.25% | -156.12% | -1,074.15% | -600,855.56% | -6,842.20% | -244.55% | 5.77% | 0.00% | 0.00% | 0.00% |
| Operating Income | -65.54M | -79.04M | -92.29M | -126.74M | -109.48M | -77.18M | -19.95M | 798.00K | -12.41M | -4.37M | -3.39M |
| Operating Income Ratio | -79.23% | -122.82% | -192.11% | -1,074.15% | -608,211.11% | -6,842.20% | -244.55% | 4.55% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -32.79M | -28.99M | -17.08M | 1.63M | 4.33M | 1.65M | -31.00K | -2.74M | -279.00K | -107.00K | 83.00K |
| Income Before Tax | -98.32M | -108.03M | -109.37M | -125.11M | -105.15M | -75.53M | -19.98M | -1.94M | -12.69M | -4.48M | -3.31M |
| Income Before Tax Ratio | -118.87% | -167.86% | -227.66% | -1,060.34% | -584,144.44% | -6,696.10% | -244.93% | -11.07% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.92M | 1.14M | 1.45M | 3.37M | -4.62M | 125.00K | 19.00K | 0.00 | 0.00 | 81.00K | 0.00 |
| Net Income | -102.24M | -109.16M | -110.82M | -128.48M | -100.53M | -75.66M | -20.00M | -1.94M | -12.69M | -4.56M | -3.31M |
| Net Income Ratio | -123.61% | -169.62% | -230.67% | -1,088.94% | -558,500.00% | -6,707.18% | -245.16% | -11.07% | 0.00% | 0.00% | 0.00% |
| EPS | -3.55 | -4.79 | -4.96 | -5.90 | -4.90 | -4.80 | -2.06 | -0.16 | -5.51 | -1.98 | -1.56 |
| EPS Diluted | -3.55 | -4.79 | -4.96 | -5.90 | -4.90 | -4.80 | -2.06 | -0.16 | -5.51 | -1.98 | -1.56 |
| Weighted Avg Shares Out | 28.83M | 22.81M | 22.35M | 21.78M | 20.53M | 15.75M | 9.72M | 11.97M | 2.30M | 2.30M | 2.12M |
| Weighted Avg Shares Out (Dil) | 28.83M | 22.81M | 22.35M | 21.78M | 20.53M | 15.75M | 9.72M | 11.97M | 2.30M | 2.30M | 2.12M |
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of...
UroGen Pharma to Participate at Upcoming Investor Conferences
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in May: Citizens JMP Life Sciences...
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first and largest real-world patient cohort review of...
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
PRINCETON, N.J--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier methods...
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from a real-world patient cohort review of JELMYTO (mitomycin) for...
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report 2024 first quarter financial results on Monday, May 13, 2024, prior...
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that new data on investigational drug UGN-102 (mitomycin) and JELMYTO and will be presented at...
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the U.S. Food and Drug Administration (FDA) accepted the Company's Investigational New Drug (IND) application...
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it has filed a lawsuit in the U.S. District Court for the District of...
UroGen Pharma Ltd. (URGN) Q4 2023 Earnings Call Transcript
UroGen Pharma Ltd. (URGN) Q4 2023 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports